229 related articles for article (PubMed ID: 32306709)
1. Impact of early anti-TNF use on clinical outcomes in Crohn's disease: a nationwide population-based study.
Jung YS; Han M; Park S; Cheon JH
Korean J Intern Med; 2020 Sep; 35(5):1104-1113. PubMed ID: 32306709
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
3. Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study.
Han M; Jung YS; Cheon JH; Park S
Yonsei Med J; 2020 May; 61(5):382-390. PubMed ID: 32390361
[TBL] [Abstract][Full Text] [Related]
4. Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study.
Agrawal M; Ebert AC; Poulsen G; Ungaro RC; Faye AS; Jess T; Colombel JF; Allin KH
Gastroenterology; 2023 Oct; 165(4):976-985.e3. PubMed ID: 37321356
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial.
Kappelman MD; Wohl DA; Herfarth HH; Firestine AM; Adler J; Ammoury RF; Aronow JE; Bass DM; Bass JA; Benkov K; Tobi CB; Boccieri ME; Boyle BM; Brinkman WB; Cabera JM; Chun K; Colletti RB; Dodds CM; Dorsey JM; Ebach DR; Entrena E; Forrest CB; Galanko JA; Grunow JE; Gulati AS; Ivanova A; Jester TW; Kaplan JL; Kugathasan S; Kusek ME; Leibowitz IH; Linville TM; Lipstein EA; Margolis PA; Minar P; Molle-Rios Z; Moses J; Olano KK; Osaba L; Palomo PJ; Pappa H; Park KT; Pashankar DS; Pitch L; Robinson M; Samson CM; Sandberg KC; Schuchard JR; Seid M; Shelly KA; Steiner SJ; Strople JA; Sullivan JS; Tung J; Wali P; Zikry M; Weinberger M; Saeed SA; Bousvaros A
Gastroenterology; 2023 Jul; 165(1):149-161.e7. PubMed ID: 37004887
[TBL] [Abstract][Full Text] [Related]
6. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease.
Hradsky O; Kazeka D; Copova I; Lerchova T; Mitrova K; Pospisilova K; Sulovcova M; Zarubova K; Bronsky J
Eur J Pediatr; 2021 Sep; 180(9):3001-3008. PubMed ID: 33876264
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.
Eriksson C; Söderling J; Karlqvist S; Bröms G; Everhov ÅH; Bergemalm D; Ludvigsson JF; ; Olén O; Halfvarson J
Dig Dis Sci; 2023 Jul; 68(7):3119-3128. PubMed ID: 36929241
[TBL] [Abstract][Full Text] [Related]
10. Practical strategy for optimizing the timing of anti-tumor necrosis factor-α therapy in Crohn disease: A nationwide population-based study.
Kwak MS; Cha JM; Ahn JH; Chae MK; Jeong S; Lee HH
Medicine (Baltimore); 2020 Mar; 99(10):e18925. PubMed ID: 32150045
[TBL] [Abstract][Full Text] [Related]
11. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors.
Oh EH; Oh K; Han M; Seo H; Chang K; Lee SH; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
PLoS One; 2017; 12(5):e0177479. PubMed ID: 28542298
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn's Disease.
Jung YS; Han M; Park S; Cheon JH
Gut Liver; 2021 Jan; 15(1):92-99. PubMed ID: 32839359
[TBL] [Abstract][Full Text] [Related]
13. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
Beilman CL; Kirwin E; Ma C; McCabe C; Fedorak RN; Halloran B
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1515-1524.e4. PubMed ID: 30056180
[TBL] [Abstract][Full Text] [Related]
14. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
15. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.
Safroneeva E; Vavricka SR; Fournier N; Pittet V; Peyrin-Biroulet L; Straumann A; Rogler G; Schoepfer AM;
Aliment Pharmacol Ther; 2015 Oct; 42(8):977-89. PubMed ID: 26271358
[TBL] [Abstract][Full Text] [Related]
16. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.
Rubin DT; Uluscu O; Sederman R
Inflamm Bowel Dis; 2012 Dec; 18(12):2225-31. PubMed ID: 22359399
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients.
Lightner AL; McKenna NP; Alsughayer A; Loftus EV; Raffals LE; Faubion WA; Moir C
J Pediatr Surg; 2019 Oct; 54(10):2162-2165. PubMed ID: 30773391
[TBL] [Abstract][Full Text] [Related]
18. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study.
González-Lama Y; Suárez C; González-Partida I; Calvo M; Matallana V; de la Revilla J; Magaz M; Bernardo C; Agudo B; Ibarrola P; Relea L; Arévalo J; Vera MI; Abreu L
J Crohns Colitis; 2016 Jan; 10(1):55-60. PubMed ID: 26520164
[TBL] [Abstract][Full Text] [Related]
19. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.
Ungaro RC; Limketkai BN; Jensen CB; Yzet C; Allin KH; Agrawal M; Ullman T; Burisch J; Jess T; Colombel JF
Clin Gastroenterol Hepatol; 2020 May; 18(5):1152-1160.e1. PubMed ID: 31419574
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity-score matched cohort analysis.
Narula N; Wong ECL; AlRamdan R; Bualbanat H; Marshall JK; Steinhart AH; Greener T; Silverberg MS
J Gastroenterol Hepatol; 2021 Oct; 36(10):2803-2812. PubMed ID: 34020510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
